Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Yuma Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$621,658

129 payments

Through program year 2025, Yuma Clinical Trials is reported as receiving $621,658 in research payments, across 129 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $258,038 120
2024 Research $333,612 4
2023 Research $4,808 2
2022 Research $25,200 3

Breakdown

Who paid Research payments · program years 2022–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $498,643 16 payments
  2. Amgen Inc. $35,834 1 payment
  3. Taro Pharmaceuticals USA, Inc. $25,200 3 payments
  4. AstraZeneca Pharmaceuticals LP $18,616 2 payments
  5. Boehringer Ingelheim International GmbH $18,357 104 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $16,662 1 payment
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $8,346 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. Obesity Long term safety in patients with CV risk $323,670 5 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $178,876 101 payments
  3. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $35,834 1 payment
  4. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $22,799 16 payments
  5. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $18,616 2 payments
  6. Finality Study #22618 $16,662 1 payment
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis $13,200 2 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis $12,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record